NVAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Novavax Inc (NVAX) is not a strong buy for a beginner investor with a long-term focus at this time. While there are some positive catalysts, such as the company's shift to a high-margin licensing model and improving gross margins, the financial performance shows significant declines in net income and EPS. Additionally, the mixed analyst ratings and lack of strong proprietary trading signals suggest that the stock does not present a compelling entry point currently. The investor may consider monitoring the stock for further developments or clearer buy signals.
The MACD is positive and expanding, indicating a bullish trend. However, the RSI is neutral at 58.659, and moving averages are converging, which does not provide a strong directional signal. The stock is trading near its resistance levels (R1: 8.679), suggesting limited immediate upside potential.
Activist pressure on governance and costs, which may lead to board refresh and balance sheet enhancements.
Shift towards a high-margin licensing model with agreements like the one with Pfizer.
Gross margin improvement to 84.98%, up 43.94% YoY.
Significant drop in net income (-121.63% YoY) and EPS (-121.57% YoY) in the latest quarter.
Mixed analyst ratings with some firms maintaining underperform or sell ratings.
Lack of recent news or major catalysts to drive immediate price movement.
In Q4 2025, revenue increased by 66.61% YoY to $147.1M, but net income dropped significantly (-121.63% YoY) to $17.5M. EPS also declined by -121.57% YoY to 0.11. Gross margin improved to 84.98%, up 43.94% YoY.
Analyst ratings are mixed. Some analysts, like B. Riley and H.C. Wainwright, have raised price targets and maintain buy ratings, citing the company's licensing model and activist pressure. However, others, like BofA and Citi, maintain underperform or sell ratings, citing concerns about development cadence and limited near-term upside.
